Blood exchange transfusion with dexamethasone and Tocilizumab for management of hospitalized patients with sickle cell disease and severe COVID-19: Preliminary evaluation of a novel algorithm

Affiliations

• ¹ Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital- UPEC, AP-HP, Créteil, France.
• ² Armand-Trousseau Hospital, Service de Pédiatrie, Center for Sickle Cell Disease, Paris, France.
• ³ Institut Universitaire du Cancer Toulouse Oncopole, Médecine Interne, Toulouse, France.
• ⁴ Department of Hematology, Hôpital Saint-Vincent de Paul, Hématologie, Lille, France.
• ⁵ Sickle Cell Center, University of the French West Indies, CHU de Martinique, Fort de France, France.
• ⁶ CHU Saint-Etienne, Médecine Interne, Saint Etienne, France.
• ⁷ Department of Pharmacy, CHU Henri Mondor, Pharmacie, Creteil, France.
• ⁸ CHU Henri Mondor, National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est Creteil, Île-de-France, France.
• ⁹ CHU Henri Mondor, Internal Medicine, Reference center of autoimmune cytopenias, Créteil, France.
• ¹⁰ Department of Intensive Care, CHU Henri Mondor, Créteil, France.
• ¹¹ Sickle Cell Referral Center, France, Internal Medicine Department, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.